Oncolytics Biotech buy El_Zocko
Start price
27.02.15
/
50%
€6.75
Target price
16.06.15
€19.00
Performance (%)
-27.75%
End price
16.06.15
€4.87
Summary
This prediction ended on 16.06.15 with a price of €4.87. The prediction for Oncolytics Biotech disappointed with a performance of -27.75%. El_Zocko has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Oncolytics Biotech | - | - | - | - |
| iShares Core DAX® | -0.197% | -1.724% | 12.342% | 55.750% |
| iShares Nasdaq 100 | -3.612% | -3.768% | 0.437% | 80.820% |
| iShares Nikkei 225® | 1.176% | 2.165% | 19.971% | 49.596% |
| iShares S&P 500 | -0.825% | -1.916% | 0.099% | 55.940% |
Comments by El_Zocko for this prediction
In the thread Oncolytics Biotech diskutieren
Runde 2 im Zock - ONCOLYTICS BIOTECH
Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.
Quelle: http://www.oncolyticsbiotech.com/
(Vom Mitglied beendet)